Belimumab shows promise in neuropsychiatric lupus:Another challenge to find the offender  

作　　者：Shuilian Yu Zhongjun Hou Zhiping Liu Zeying Lin Ling Zhong Qilin Yang Wenhui Huang 

机构地区：[1]Department of Rheumatology,Second Affiliated Hospital,Guangzhou Medical University,Guangzhou,Guangdong,China [2]Department of Radiology,Second Affiliated Hospital,Guangzhou Medical University,Guangzhou,Guangdong,China [3]Ophthalmic Center,Second Affiliated Hospital,Guangzhou Medical University,Guangzhou,Guangdong,China [4]Department of Pathology,Second Affiliated Hospital,Guangzhou Medical University,Guangzhou,Guangdong,China [5]Department of Critical Care,Second Affiliated Hospital,Guangzhou Medical University,Guangzhou,Guangdong,China

出　　处：《Rheumatology & Autoimmunity》2023年第2期115-119,共5页风湿病与自身免疫（英文）

基　　金：Nature Science Foundation Project of Guangdong Province,Grant/Award Number:2019A1515011094。

摘　　要：Introduction:Agents that can be used for the treatment of neuropsychiatric lupus(NPSLE)are lacking in the therapeutic armamentarium.Belimumab is a monoclonal antibody targeting the B-cell activating factor(BAFF)and is approved by the US Food and Drug Administration as an additional treatment for systemic lupus erythematosus patients with persistent disease activity and lupus nephritis(LN);however,severe active central nervous system manifestations were excluded.Case Report:We report on a treatment-naïve LN patient with refractory NPSLE complicated with progressive posterior reversible encephalopathy syndrome(PRES)who was successfully treated via the combination of mycophenolate and belimumab,resulting in reversal of persistent headache and neuroradiologic manifestations.Conclusion:Research on this topic could be relevant for identifying a possible correlation between BAFF and psychiatric NPSLE manifestations.

关 键 词：BELIMUMAB lupus nephritis neuropsychiatric lupus posterior reversible encephalopathy syndrome 

分 类 号：R593.2[医药卫生—内科学]